Distressed M&A in healthcare is the purchase of a hospital or provider business when the seller is short on cash, under lender pressure, facing regulatory findings, or close to insolvency. A “363 sale” is a court-approved asset sale in bankruptcy that can transfer assets with a sale order that helps clear liens and limit certain claims. A CHOW – change of ownership – is the licensure and payer enrollment process that decides whether you can legally operate and bill after control changes.
In this corner of finance, the low price is rarely the headline. The headline is the clock. Time, cash control, and third-party consents decide what you can buy, how you can buy it, and whether you can keep the doors open long enough to get paid.
Why distressed healthcare deals are won on continuity, not just price
Distress in healthcare usually shows up as vendor arrears, payroll strain, payer recoupments, and a revenue cycle that has slipped from “messy” to “unreliable.” It also shows up as quality-of-care findings that put licensure or payer participation at risk. A smart buyer underwrites not only enterprise value, but “continuity value” – the value preserved by avoiding service interruption, license actions, and staff flight.
Continuity value is the real asset, and it evaporates quickly. Therefore, distressed healthcare M&A doesn’t replace a turnaround plan. It is a control transfer and recapitalization tool that must hold up against creditor scrutiny. Done with discipline, it preserves patient access, steadies the workforce, and often yields better creditor recoveries than a shutdown.
Done carelessly, it turns a liquidity issue into a regulatory and reputational spectacle, and the value goes with it. The payoff for buyers is clear: if you can keep billing and clinical operations stable while fixing the underlying cash burn, you can buy durable demand at a distressed entry cost.
Choose the right lane: out-of-court, 363, or state-law tools
1) Out-of-court sales can work when the runway is real
First, an out-of-court change-of-control sale is usually a strategic buyer or sponsor stepping in with new liquidity. It works best when the seller is still making payroll and can maintain licenses and payer participation during the marketing window. However, you still need a negotiated forbearance or payoff with secured lenders and a plan for critical trade creditors who can stop supplies.
2) Section 363 sales help when liens, claims, or governance are tangled
Second, a Section 363 asset sale in bankruptcy is used when liens are tangled, litigation risk is real, or the buyer needs a sale order to support clean title, contract assignment mechanics, and a stronger defense against successor arguments. It also helps when the existing management team has lost credibility and the process needs a referee. A 363 process is not instant, but it can be faster than trying to reconcile hostile creditor groups in private.
If you want a deeper primer on mechanics and what a sale order can and cannot do, see bankruptcy Section 363 sales.
3) Receivership and ABCs can be faster, but they break down in complex systems
Third, receivership or an assignment for the benefit of creditors (ABC) can move quickly and cost less than Chapter 11, especially for a single facility with a narrow creditor set. These tools get weaker with multi-state systems, multiple regulated entities, Medicaid change-of-ownership rules, and payer contracts that do not fit neatly into state-law machinery.
Healthcare “closing” is a coordinated handoff, not a single moment
The boundary conditions in healthcare are tighter than in most industries. Licensure, certificate of need (CON) rules in some states, Medicare/Medicaid enrollment, payer network status, and controlled substance registrations can be non-transferable or require approvals and time. So closing is often a coordinated handoff of clinical operations, billing identity, contracts, and licenses, with interim services and cash-control bridges.
If your model assumes a clean switch on Day 1, your model is a story. A useful rule of thumb is to treat the first 90 days as a separate underwriting case with its own “survival economics,” then layer the full turnaround case on top.
Why distress still produces saleable healthcare targets
Healthcare distress often comes from working capital and reimbursement timing rather than a collapse in demand. A hospital can have steady volumes and still fail because collections slow, denials rise, or rates do not keep up with costs. That is why distressed healthcare can be attractive: if you can fix revenue cycle performance, stabilize labor, and fund operations through the transition, you may be buying a durable stream of demand at a price that reflects temporary disorder.
Cost pressure is a recurring catalyst. The American Hospital Association reported hospital expense growth of 17.5% from 2019 to 2022, while inflation-adjusted reimbursement rose materially less over the same period (as of Apr-2024). That mismatch creates negative operating leverage in high fixed-cost facilities. If you do not underwrite labor and supply costs as the main driver of near-term cash burn, you will misprice the bridge capital and jeopardize close certainty.
Liquidity is also sensitive to payer audits and recoupments. Medicare and Medicaid findings can turn into immediate cash drains through offsets. Commercial payers increasingly use post-pay review and extrapolation. In distress, those are not footnotes; they are deal terms because they can break your first 13-week cash forecast.
Behavior matters, too. Many operators delay restructuring because of mission pressure and community optics. That delay compresses the sale timeline and wears down staff and physicians. As a result, a buyer should assume less time for diligence and more execution risk than the spreadsheet suggests.
Define the asset: what are you actually buying?
The first investment committee question should be plain: is the value in licenses and contracts, in hard assets, or in a going-concern platform with repeatable cash flow? If you cannot answer that cleanly, you cannot pick structure, and you cannot set an offer that survives contact with reality.
Hospitals and provider groups are rarely one company. They are a set of entities for real estate, operations, employed physicians, management services, and sometimes a foundation. Distress can sit in one entity while cash and assets sit elsewhere. Before you argue price, map legal entities to cash flow, liabilities, and regulated approvals.
Three common acquisition packages (and what they trade off)
- Asset purchase: Buy operating assets and exclude most historical liabilities, paired with new payer enrollments and selective contract assumptions. This is common in 363 sales and out-of-court “newco” structures, but billing disruption risk rises if payer transitions lag.
- Equity purchase: Buy an enrolled, contracted entity when payers will not credential a new entity fast enough. This improves billing continuity but brings liabilities closer, including employment, tax, and False Claims Act risk.
- Hybrid structure: Acquire assets but bridge operations under a management agreement or use a shell for specific licenses or contracts while approvals pend. This often preserves continuity, but documentation and compliance drafting must be tighter.
A common misconception is that a 363 sale eliminates all risk. It can improve title and reduce certain claims, but it does not automatically solve licensure, Medicare enrollment, controlled substance registrations, or professional liability tail. It also does not solve staff retention, physician alignment, or payer behavior. Courts can bless a sale; they cannot make people show up for work.
Approvals set the timetable, and distress does not pause them
Healthcare approvals decide whether a deal can close on the seller’s liquidity runway. Regulators may move faster when closure risk is real, but “may” is not a financing plan. Therefore, buyers should build a critical-path chart with owners, dates, and fallback structures.
State licensure and CHOW rules often require prior notice or approval. If the approval period exceeds the runway, buyers use interim management agreements or lease-and-operator structures to bridge. Those bridges must avoid unlicensed operation and prohibited fee-splitting, so the compliance logic needs to be simple and defensible.
Medicare and Medicaid enrollment is its own gating item. CMS policies govern provider enrollment changes and assignment of provider agreements. Enrollment timing affects cash flow directly, which is why many buyers keep an existing enrolled entity and buy equity to avoid billing disruption and accept the liability trade-off.
CON regimes can block or slow transfers in certain states. Treat CON as a critical path item and underwrite probability and timing. If your return depends on a fast CON approval, you do not have a return; you have a request.
Privacy and security matter because HIPAA constrains data transfer and business associate arrangements. Distressed targets often have weak security posture. You can limit data exposure by using de-identified extracts where possible, restricting access by role, tracking file views and downloads, and separating a clean team when payer or pricing data is competitively sensitive.
Fraud and abuse rules – the Anti-Kickback Statute (AKS), Stark Law, and state fee-splitting rules – constrain how you provide financial support during transition. Retention payments, management fees, and medical director arrangements should tie to services and fair market value with clear documentation. If you use cash as a blunt tool, you can buy yourself a regulatory file that outlives the deal.
Antitrust and state attorney general review can also appear, especially for hospital combinations. The FTC and DOJ have been active in healthcare and updated merger guidelines in Dec-2023, and a “failing firm” narrative has a high evidentiary bar and often does not fit the seller’s cash clock.
Cash control is the first operational plan
A deal that closes but cannot fund operations is a deal that failed, just on a short delay. Flow-of-funds planning is an operating plan because distressed providers often live under cash dominion, where lenders sweep receipts daily.
If you do not release dominion or replace it with new controls, your post-close collections may go to yesterday’s lender. Buyers should assume post-close cash is not sitting in the target’s accounts waiting politely.
- New accounts: Open buyer-controlled depository accounts and implement an authority matrix for disbursements.
- Collections plumbing: Transition payer EFTs, lockboxes, and merchant services for patient payments with tracked confirmations.
- 13-week forecast: Build a conservative 13-week cash flow with explicit reserves for payer offsets and recoupments.
- A/R clarity: Define exactly what accounts receivable you are buying and what remains encumbered or with the estate.
When A/R is a primary asset, precision matters. In many 363 sales, the buyer takes selected A/R and leaves prepetition A/R with the estate, which reduces working capital value but also reduces entanglement with offsets, disputes, and old billing questions. In out-of-court deals, if you fund operations pre-close, structure priority. Unsecured rescue funding is often a gift.
Documentation that actually matters in distressed healthcare
Distressed healthcare deals are paper-heavy because they allocate regulatory and continuity risk, not just price. The letter of intent (LOI) or term sheet should set structure, assumed liabilities, exclusivity, milestones, access rights, and any cash support. In distress, milestones and access are how you keep the process from drifting while the business bleeds.
The asset purchase agreement (APA) or stock purchase agreement (SPA) allocates assets, liabilities, and transition obligations. In 363, it must work with bidding procedures and the sale order. Transition services agreements (TSAs) often run in the opposite direction from normal deals, with the buyer sometimes providing services to the seller during wind-down.
MSO and management agreements, where needed, must fit corporate practice rules and fraud-and-abuse constraints. Real estate documents such as leases, assignments, and SNDAs often decide whether operations are even possible. Financing documents and cash management agreements decide whether you can control cash on Day 1.
Reps and warranties are often thin. In distress, the seller may not have the balance sheet to stand behind indemnities, so protection shifts back to diligence and structure. R&W insurance can help in some stressed but solvent situations, but in true distress, underwriting and recourse are constrained.
Economics: three prices, one outcome
Distressed economics are driven by three prices. First is the purchase price. Second is stabilization capital for payroll, supplies, revenue cycle remediation, and often IT and security work. Third is assumed liabilities and cure costs, including cure payments for assumed executory contracts and leases in a 363 sale.
Bankruptcy professional fees are real economics that reduce estate value and shape negotiations. Sometimes the buyer funds certain fees through bid terms, so they should be treated as transaction costs that affect total consideration and optics.
A cheap asset can be expensive if you must fund weeks of payroll and supplies while collections lag. Underwrite liquidity as a first-lien risk. If your plan survives only if collections accelerate immediately, you are betting on hope, not process.
Financial reporting and covenant risk buyers underestimate
Distressed provider financials are often not audit-ready. Revenue recognition, contractual allowances, and bad debt policies can be inconsistent. For hospitals with complex payer mixes, net patient service revenue rests on estimates that can drift in distress.
A quality-of-earnings review should focus on the gross-to-net waterfall by payer, denials and appeals aging, settlement exposure, concentration risk, and related-party arrangements. If you need a diligence process refresher, see M&A due diligence.
If you use acquisition financing, EBITDA-based covenants can be fragile because EBITDA swings with revenue cycle normalization and temporary staffing costs. Lenders respond by tightening definitions, capping add-backs, and requiring weekly reporting, and those terms often decide whether you keep control long enough to fix the business.
MSO structures can also create consolidation issues under ASC 810. If control comes through contracts rather than equity, variable interest entity (VIE) analysis can change reporting leverage and lender appetite. Bring accounting advisors in early because it is cheaper than renegotiating covenants after close.
Diligence priorities: the must-not-break list
In distressed healthcare, diligence should focus on items that can stop billing, trigger exclusion, or create immediate cash drains. Confirm Medicare and Medicaid participation status, revalidation dates, and pending adverse actions. Identify audits and recoupment exposure and model cash impact under offset scenarios.
Review survey history, immediate jeopardy events, and corrective action plans because these affect licensure risk and staff morale. Assess cybersecurity and incident history because operational plumbing matters. The Change Healthcare cyberattack in early 2024 disrupted claims across the system and reminded everyone that a weak environment can become a platform-wide problem after integration.
Analyze physician arrangements and referral relationships for Stark and AKS exposure. Review labor dependence on agency staffing, union status, accrued PTO, and benefits. Validate real estate, equipment maintenance, and deferred capex because these items hit timing, cost, and regulatory posture quickly.
Governance: control without breaking continuity
Distressed deals often unravel after signing because governance is vague. Governance is how you protect cash and compliance while still keeping the clinical machine running.
- Operating covenants: Limit non-ordinary actions, cap discretionary spend, and require weekly cash reporting.
- Decision rights: Define who can hire, fire, and approve service line changes, then align those rights with licensure limits.
- Step-in rights: If interim funding is provided, include step-in rights for cash management on breach, drafted to avoid unlicensed operation.
- Information rights: Require bank reporting, payer portal access, and system audit trails so you can see problems before they become defaults.
In distress, “we didn’t know” is not an acceptable answer to lenders or regulators. For related execution discipline, the checklist mindset used in distressed deal team toolkits translates well to regulated healthcare closings.
Early kill tests that save capital and time
Before spending heavily on confirmatory diligence, run blunt tests. Can you legally operate and bill within the liquidity runway? If approvals will not line up, structure a compliant bridge or walk. Can you control cash? If you cannot control bank accounts, lockboxes, and visibility into payer portals, pause.
Are liabilities containable? If billing integrity issues point to credible False Claims Act exposure or exclusion risk, structure will not cure it. Will medical staff stay? If physicians or key teams leave on announcement, continuity value disappears, and retention tools must be compliant and executable.
Is real estate separable and financeable? If you cannot clear liens or secure a workable lease, operations can be stranded. Does the process create defensibility? If creditors will attack, you need a record of fair process and value, and court supervision may be worth the time. For a broader process lens, see distressed M&A timelines.
What buyers should demand early (to avoid flying blind)
Distress creates asymmetry. Sellers want speed and confidentiality, while buyers need transparency and control. At a minimum, demand a full entity chart with intercompany cash movements, a lien search with payoff letters by collateral, payer mix detail with a gross-to-net bridge supported by extracts, an audit and recoupment schedule, licensure and survey history with corrective action plans, key contracts with assignment and change-of-control terms, A/R aging with denial codes, bank and lockbox details with payer EFT information, and a clear cyber incident history with a current posture assessment.
If the seller cannot produce this promptly, assume the deal needs court supervision or decline it. This is also where diligence hygiene becomes a value lever: treat information as an asset, not a courtesy.
Closing Thoughts
Distressed healthcare M&A is a regulated continuity transaction wrapped in an acquisition. The sound thesis is rarely “buy low and wait.” It is “buy control, preserve billing continuity, and fund a specific stabilization plan with enforceable cash governance.” An investment committee should insist on a regulatory and payer critical path, a liquidity plan tied to controllable cash from Day 1, and a defensibility plan that anticipates creditor and regulator scrutiny.